Drug Approval | November 22, 2023
Truqap plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
